About this trial
This study is a single-center, randomized, double-blind, placebo-controlled trial.
Eligibility criteria
Qualifiers
Clinical diagnosis of sepsis-induced gastrointestinal dysfunction with Acute AGI grade I-III.
50-90 years old, regardless of gender.
Sequential Organ Failure Assessment (SOFA) score ≥ 2.
Diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours.
Disqualifiers
ICU length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible.
Patients with allergies or allergic constitution to the investigational herbal medications.
Inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight > 150 kg), trauma, or surgical factors.
Severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, HIV, etc.
Trial design
Treatments tested in this trial
- Fuzheng Tongfu Jiedu prescription (FZTFJD)
- Placebo
Treatment groups
Sponsors and collaborators
Dongzhimen Hospital, Beijing
Lead sponsor
Beijing University of Chinese Medicine
Collaborator